Cytek Biosciences, Inc. is a life sciences technology company engaged in the provision of cell analysis tools by leveraging novel technical approaches.
Company profile
Ticker
CTKB
Exchange
Website
CEO
Wenbin Jiang
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Cytek (Shanghai) Biosciences Co., Ltd. • Cytek (Wuxi) Biosciences Co. Ltd. • Cytek Biosciences B.V. • Cytek Japan Corporation • Cytek Biosciences Ltd • Cytek Biosciences GmbH • Cytek Limited ...
IRS number
472547526
CTKB stock data
Latest filings (excl ownership)
SD
Conflict minerals disclosure
31 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Cytek Biosciences Reports First Quarter 2024 Financial Results
8 May 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
8-K
Cytek® Biosciences Names William McCombe Chief Financial Officer
19 Mar 24
S-8
Registration of securities for employees
14 Mar 24
10-K
2023 FY
Annual report
13 Mar 24
NT 10-K
Notice of late annual filing
1 Mar 24
Transcripts
CTKB
Earnings call transcript
2024 Q1
8 May 24
CTKB
Earnings call transcript
2023 Q4
28 Feb 24
CTKB
Earnings call transcript
2023 Q3
7 Nov 23
CTKB
Earnings call transcript
2023 Q2
8 Aug 23
CTKB
Earnings call transcript
2023 Q2
8 Aug 23
CTKB
Earnings call transcript
2023 Q1
9 May 23
CTKB
Earnings call transcript
2022 Q3
9 Nov 22
CTKB
Earnings call transcript
2022 Q2
11 Aug 22
CTKB
Earnings call transcript
2022 Q1
12 May 22
CTKB
Earnings call transcript
2021 Q4
24 Feb 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 169.14 mm | 169.14 mm | 169.14 mm | 169.14 mm | 169.14 mm | 169.14 mm |
Cash burn (monthly) | (no burn) | (no burn) | 3.58 mm | 1.85 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 7.39 mm | 3.81 mm | n/a | n/a |
Cash remaining | n/a | n/a | 161.75 mm | 165.33 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | 45.2 | 89.5 | n/a | n/a |
Institutional ownership, Q4 2023
4.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 2 |
Closed positions | 98 |
Increased positions | 3 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 922.04 mm |
Total shares | 5.90 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
3E Bioventures Capital | 5.68 mm | $0.00 |
State of Alaska, Department of Revenue | 60.87 k | $555.00 k |
New York State Teachers Retirement System | 54.48 k | $497.00 k |
Mirae Asset Global Investments | 49.05 k | $447.36 mm |
Arizona State Retirement System | 32.40 k | $295.50 mm |
Mutual Of America Capital Management | 17.32 k | $157.95 mm |
Nisa Investment Advisors | 1.36 k | $12.36 mm |
FITB Fifth Third Bancorp | 756.00 | $6.90 mm |
Valley National Advisers | 120.00 | $1.00 k |
Farmers & Merchants Investments | 60.00 | $547.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 May 24 | Philippe Busque | Common Stock | Payment of exercise | Dispose F | No | No | 5.96 | 574 | 3.42 k | 8,299 |
20 May 24 | Philippe Busque | Common Stock | Option exercise | Acquire M | No | No | 0 | 1,473 | 0.00 | 8,873 |
20 May 24 | Philippe Busque | Common Stock | Payment of exercise | Dispose F | No | No | 5.96 | 2,594 | 15.46 k | 7,400 |
20 May 24 | Philippe Busque | Common Stock | Option exercise | Acquire M | No | No | 0 | 6,659 | 0.00 | 9,994 |
20 May 24 | Philippe Busque | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,473 | 0.00 | 33,887 |
20 May 24 | Philippe Busque | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 6,659 | 0.00 | 17,931 |
20 May 24 | Valerie Barnett | Common Stock | Payment of exercise | Dispose F | No | No | 5.96 | 2,009 | 11.97 k | 42,044 |
20 May 24 | Valerie Barnett | Common Stock | Option exercise | Acquire M | No | No | 0 | 5,156 | 0.00 | 44,053 |
20 May 24 | Valerie Barnett | Common Stock | Payment of exercise | Dispose F | No | No | 5.96 | 956 | 5.70 k | 38,897 |
20 May 24 | Valerie Barnett | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,454 | 0.00 | 39,853 |
News
Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $8.5
13 May 24
Cytek Biosciences, Inc. Reports Q1 Loss, Tops Revenue Estimates
9 May 24
Cytek Biosciences Q1 2024 Adj EPS $(0.05) Misses $(0.04) Estimate, Sales $44.900M Beat $43.586M Estimate
8 May 24
Cytek Biosciences Names William McCombe Chief Financial Officer; Reaffirms 2024 Revenue Outlook Of $203M-$213M Vs $207.86M Est.
19 Mar 24
Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $10
6 Mar 24
Press releases
Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference
30 May 24
1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China
28 May 24
Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems
20 May 24
Cytek Biosciences Reports First Quarter 2024 Financial Results
8 May 24
Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe
30 Apr 24